TIPAL: The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole, a randomised placebo-controlled multi-centre clinical trial
The TIPAL research study is focusing on treating idiopathic pulmonary fibrosis (IPF) with the addition of lansoprazole. Lansoprazole reduces the amount of acid your stomach makes. It’s used for indigestion, heartburn, acid reflux and gastroesophageal-reflux-disease (GORD). Lansoprazole is also taken to prevent and treat stomach ulcers (see NHS, nd).
Research Question: Does anti-reflux therapy slow the deterioration of lung function and improve morbidity in Idiopathic Pulmonary Fibrosis (IPF)? Background: IPF, a progressive fibrotic interstitial lung disease, has a poor prognosis and limited treatment options. Observational data suggest that anti-acid therapy is beneficial in IPF and current international guidelines cautiously advise their use. There are no randomised controlled trials of anti-acid therapy but all reviews advocate one.
Chief Investigator(s):
Co-investigators:
Dr Chris Ward, Dr Helen Parfrey, Dr Ian Forrest, Dr Lisa Spencer, Dr Nazia Chaudhuri, Mr Ian Perry, Mr Shajahan Wahed, Mr Stephen Jones, Professor Allan Clark, Professor Ann Marie Swart, Professor David Thickett, Professor Jaclyn Smith, Professor John Simpson, Professor Toby Maher
Funding: This study/project is funded by the NIHR Health Technology Assessment Programme (NIHR 127479).
TIPAL is registered on the ISRCTN Trial Registry: ISRCTN13526307 and ClinicalTrials.Gov
TIPAL research study website.
Duration of study: June 2021 to August 2024.
Response article: “Anti-Acid Therapies in Idiopathic Pulmonary Fibrosis: Premature to Dismiss?.” American Journal of Respiratory and Critical Care Medicine, 0(ja), pp. – . Louise E Crowley, Andrew Wilson, David R Thickett Corresponding Author – lxc097@bham.ac.uk 07883203405. View article HERE.
Lansoprazole: Information about the anti-acid medication Lansoprazole, including side-effects, can be found on the NHS website.